CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...